Drug Profile


Alternative Names: VSN-16R

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Canbex Therapeutics; University College London
  • Developer Canbex Therapeutics
  • Class Small molecules
  • Mechanism of Action Cannabinoid receptor modulators; G-protein-coupled receptor 55 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Muscle spasticity

Most Recent Events

  • 24 Feb 2015 Ipsen signs an option agreement to acquire Canbex Therapeutics
  • 24 Feb 2015 Canbex plans a phase IIa trial for Multiple Sclerosis
  • 16 Jan 2015 Phase-II clinical trials in Muscle Spasticity in United Kingdom (PO) - EudraCT2014-004412-11
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top